Live·Open questions in longevity research
All news
Longevity researchTherapeutics

Among US patients who survived a year with a transplanted kidney, age at death showed no statistically significant difference with or without rapamycin: after balancing the groups, half had died by age 64,6 with rapamycin and 64,3 without it

11 November 2026· 261111004

Among US patients who survived a year with a transplanted kidney, age at death showed no statistically significant difference with or without rapamycin: after balancing the groups, half had died by age 64,6 with rapamycin and 64,3 without it

Darren Stewart (New York University) and William Fitzsimmons (University of Illinois Chicago) used the US transplant registry to compare 4885 kidney recipients taking rapamycin with 6589 who were not. The study was published on November 5 in GeroScience.

Rapamycin (sirolimus) inhibits mTOR, a protein that regulates cell growth. It has been prescribed in the US after kidney transplantation since 1999 to suppress the immune system and prevent rejection of the donor organ. In a 2009 experiment published in Nature, rapamycin extended lifespan in mice. When treatment began on day 600 of life, the age at which 10% of the animals remained alive increased relative to controls by 14% in females and 9% in males. The authors examined the human evidence in kidney transplant recipients: thousands of patients received rapamycin in the 2000s, and the registry records their treatment regimens and is updated with dates of death from external databases.

The analysis included adults who received a single kidney transplant in 2000–2007 and were alive with a functioning transplant a year later. All were taking tacrolimus or cyclosporine to prevent rejection. One group also had rapamycin recorded in its treatment regimen both at discharge and a year later (96,5% were taking sirolimus and the rest the related drug everolimus); the other group had it recorded at neither timepoint. During the second through fifth years, rapamycin was recorded at 75% of visits in the first group and 3% in the second.

Patients taking rapamycin were younger (median age 48 years versus 51,9) and twice as likely to take cyclosporine (41,6% versus 21,1%). Rapamycin prescribing declined in the early 2000s, while clinics were also switching from cyclosporine to tacrolimus. The authors estimated survival in two ways. They either ended follow-up when the transplanted kidney failed, since rapamycin was presumably discontinued at that point, or continued follow-up until death or the end of 2025, because ending it at transplant failure could bias the estimate.

Before adjustment, the first approach estimated that half the rapamycin group had died by age 63,8, compared with 66,7 in the control group, a gap of 2,9 years. The authors then balanced the groups on 18 characteristics, including age and year of transplantation. After adjustment, half the rapamycin group had died by age 66,1 versus 66,7 in the control group under the first approach, and by 64,6 versus 64,3 under the second. The differences of −0,6 and +0,3 years were within the range of chance variation.

The authors acknowledge a possible objection: transplant recipients usually take high daily doses of rapamycin, whereas people taking it for longevity use low doses once a week. They respond by comparing doses used in mice: according to the evidence they cite, doses of 2–22 mg per kilogram of body weight per day extended lifespan, while doses of 2–4 mg suppressed rejection. They conclude: “Daily doses of rapamycin sufficient to suppress the immune system in organ transplantation have extended lifespan in mice.”

Earlier studies found a higher risk of death with mTOR inhibitors. In an analysis of 139 370 US recipients, the risk of death during the second through eighth years was 25% higher with a regimen in which an mTOR inhibitor replaced tacrolimus or cyclosporine. In a pooled analysis of 21 trials, sirolimus reduced cancer risk by 40% and increased the risk of death by 43%.

Two short trials tested weekly rapamycin. In RAPA-EX-01, it provided no additional exercise benefit in older adults: the number of chair stands completed in 30 seconds increased no more than in the placebo group; in PEARL, it had no effect on fat surrounding the internal organs. Taking these trials into account, the authors conclude: “At present, the use of rapamycin for longevity lacks empirical support.” They write that resolving the question will require studies in dogs and humans using different dosing regimens.

Originally published on Telegram by Ukhvat NewsView on Telegram
Sources
#rapamycin#sirolimus#mtor#kidney-transplantation#survival